The Chinese team looks forward to their next match after..
In Pfizer Inc’s continued efforts to reduce the impact of COVID-19, the wonder pill can help prevent COVID-19 infection in its early stages.
U.S pharmaceutical firm Pfizer Inc has created another breakthrough in its battle against the COVID-19 pandemic by developing an oral drug that can help halt COVID-19 in the early stages of its course.
On Monday, Pfizer Inc. announced that it has begun a large study to test its investigational oral antiviral drug for the prevention of COVID-19 infection among individuals who have been exposed to the disease.
A report by Reuters says the drugmaker’s mid-to-late-stage study on its antiviral oral drug, PF-07321332, will be testing up to 2,660 healthy adult participants aged 18 and older, who reside in the same household as an individual with a confirmed symptomatic COVID-19 infection.
The firm has also started another study on PF-07321332 in symptomatic adult patients who are not hospitalized.
Along with Pfizer, rival drugmakers such as U.S.-based firm Merck & Co Inc (MRK.N) and Swiss pharmaceutical Roche Holding AG (ROG.S) are all in a race against time to develop an easy-to-administer antiviral pill versus COVID-19.
Drugmaker Merck and partner Ridgeback Biotherapeutics have recently started a late-stage trial on their experimental drug called molnupiravir for the prevention of COVID-19 among adults in the same household as someone who tested positive with symptomatic coronavirus infection.
Reports state molnupiravir is currently being studied in non-hospitalized patients to test if it reduces risks of hospitalization or death.
Video Articles